Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Lowered by StockNews.com

Oramed Pharmaceuticals (NASDAQ:ORMP) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Thursday.

Oramed Pharmaceuticals Stock Performance

Shares of ORMP stock opened at $2.17 on Thursday. The stock has a 50 day moving average price of $2.36 and a 200 day moving average price of $2.37. The firm has a market capitalization of $87.48 million, a P/E ratio of 19.73 and a beta of 1.66. Oramed Pharmaceuticals has a 52-week low of $2.00 and a 52-week high of $3.67.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. BML Capital Management LLC lifted its holdings in Oramed Pharmaceuticals by 62.1% during the 3rd quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company’s stock valued at $5,334,000 after buying an additional 837,153 shares in the last quarter. Peapod Lane Capital LLC purchased a new position in shares of Oramed Pharmaceuticals during the fourth quarter worth approximately $550,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Oramed Pharmaceuticals during the third quarter valued at approximately $272,000. Renaissance Technologies LLC boosted its holdings in shares of Oramed Pharmaceuticals by 89.0% in the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock valued at $593,000 after purchasing an additional 108,700 shares during the period. Finally, Marquette Asset Management LLC bought a new position in Oramed Pharmaceuticals in the fourth quarter worth approximately $81,000. 12.73% of the stock is currently owned by institutional investors.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.